The histological grade of atypia is a known prognostic indicator for breast cancer patients and correlates with many gene and chromosome alterations. To investigate the independent prognostic significance of gene and chromosome alterations in axillary node-neqatlve (nO) breast cancers of the invasive ductal and invasive lobular types, the prevalence of eight gene and chromosome alterations and their association with histological grade and recurrence was studied in 129 consecutive patients who had undergone resection over an average follow-up period of 43.4 months. Loss of heterozygosity on 16q, 17p, 16p, 17q and 18q, p53 gene mutation and c-erbB-2 and int-2 gene amplifications were detected in 55°,/0, 37°,/0, 25%, 240/0, 22%, 23°,/0, 15% and 11 % respectively. Individual alterations in 17p, 17q, 18q, c-erbB-2 and p53 were detected most frequently and gene and chromosome alterations tended to be accumulated in Grade 3 nO invasive ductal/lobular carcinomas. Histological grade, 18q, int-2 and the number of these gene and chromosome alterations were significant prognostic indicators on Cox's univariate proportional hazard model, and 18q and int-2 were still significant after adjustment for histological grade. Results suggested that examination of the presence of certain gene and chromosome alterations, as well as histological grade, were effective in identifying nO breast cancer patients at high risk of early recurrence.
INTRODUCTION
The 10-year disease-free survival rate in patients with node-metastasis-negative (nO) primary breast carcinomas after curative surgical therapy has been reported as 80-90% in Japanese and 60-70% in Caucasian patients (1) (2) (3) (4) (5) . Identification of a high-risk nO breast carcinoma group would be helpful because it would allow adjuvant therapies to be targeted on this group, thus potentially resulting in an improved prognosis. A number of histological, biochemical and immunohistochemical factors have been reported as being effective prognostic indicators in nO breast carcinoma. Histological type, histological grade, nuclear grade and the number of mitotic figures of cancer cells are pure morphological prognostic indicators in the nOgroup (5) (6) (7) (8) (9) (10) . Ductal carcinoma in situ (DeIS) , invasive ductal carcinoma with a predominantly intraductal component, or predominantly DCIS, medullary carcinoma and mucinous carcinoma have been shown to recur only rarely after curative surgery and are accepted as low-risk groups. In invasive ductal carcinoma (IDC), the highest histological grade (Grade 3), is associated with a higher recurrence rate than lower grades (6) (7) (8) (9) (10) . A case-control study revealed that patients with Grade 3 nO IDC have a relative risk of early recurrence and death nearly 42 times higher than that of Grade 1 patients (11). If the evaluation of these histological parameters is performed objectively and reproducibly, histological type and grade would provide critical information with a strong impact on the prognosis. In addition to these histological parameters, tumor size on palpation, estrogen-receptor (ER) and progesterone-receptor (PgR) status, DNA aneuploidy, the S-phase fraction, expression of the epidermal growth factor receptor, nuclear immunoreaction of the p53 protein, microvessel density and loss of expression of the bcl-2 oncoprotein, which are detected by biochemical or immunohistochemical assays, are also known to have prognostic significance in nO breast cancer (1) (2) (3) (9) (10) (11) (12) (13) (14) (15) . Nonetheless, the consensus is that there is no single factor which can accurately identify the high-risk nO group and a combination of several factors must be used in practice to select patients likely to fall into this group (16). There are strong correlations between the histological grade of atypia in breast carcinoma (comprising I, structural atypia; II, nuclear atypia; ill, the number of mitotic figures), and the number of gene and chromosome alterations at the DNA level, e.g. amplifications ofoncogenes, chromosome alterations such as loss of heterozygosity (LOH) on chromosomes 7q, IIp, 17p and 17q and point mutation of the p53 tumor-suppressor gene (17) (18) (19) (20) (21) . These gene and chromosome alterations are most commonly detected in breast cancers with the highest histological grade, although certain chromosome alterations, e.g. LOH on 16q, are frequently detected in cancers regardless of their histological grade but do not occur in benign neoplasms of the breast.
To determine the prognostic significance of histological grade and gene and chromosome alterations in nO breast cancers, we prospectively examined the incidence of eight gene and chromosome alterations and their association with histological grade and with cancer recurrence in 129 patients with IDC/invasive lobular carcinoma (ILe). The prognostic significance of the number of gene and chromosome alterations was also analyzed.
PATIENTS AND METHODS

HISTOLOGICAL TypING AND GRADING OF NO BREAST CANCER
Fresh breast cancer and non-cancerous tissue specimens were obtained from 167 Japanese patients with nObreast carcinoma who underwent curative surgery at the hospital between June 1990 and December 1992. Except for one patient who underwent quadrantectomy and lymph node dissection with radiation therapy, in whom the surgical margins were free of cancer, radical mastectomies were performed on all patients. We confirmed that the tumor tissue specimens contained >50% of the cancer cell area by histological observation of the tissue sections adjacent to the specimens.
Histological typing of the primary tumor was performed according to World Health Organization (WHO) criteria (22) . Thirty-two patients were found to have DCIS or predominantly DCIS, 125 IDC, four ILC, three mucinous carcinoma, two medullary carcinoma and one tubular carcinoma. The criteria for histological grading of IDC were based on a modification of those recommended by the WHO (Table 1 ) (23) . These criteria were also applied to ILC, in which the score for structural atypia was always three. This grade was also allocated to the invasive components in carcinoma with an invasive component. When there was heterogeneity in the grade within a tumor specimen, the higher grade was adopted if the region with the higher grade comprised~10% of the primary tumor area while the lower grade was assigned ifthe area with the higher grade comprised <10% of the specimen. Twenty IDC specimens were classified as Grade 1,46 as Grade 2 and 59 as Grade 3. One ILC was classified as Grade 2 and three as Grade 3.
FOLLOW-UP DATA
Thirty-eight patients with low-risk histological types, i.e., DCIS or predominantly DCIS, mucinous carcinoma, medullary carcinoma or tubular carcinoma were excluded from the analysis, since only one patient with a predominantly DCIS type tumor suffered a lung metastasis 44 mo after surgery. In these 38 patients, the mean follow-up period after surgery was 42.6 mo. We examined the association between gene and chromosome alterations and prognosis in the remaining 129 patients with nO IDC/ILC. These patients, aged from 29 to 83, comprised 60 pre/perimenopausal and 69 postmenopausal patients; 40 with tumors~2.0 em in diameter, 81 with 2.1-5.0 em diameter tumors and eight with tumors~5.l ern in diameter on palpation; 95 positive for ER (>10 fmol/mg protein), 22 negative for ER ($10 fmol/mg protein) and 12 with no data regarding ER status; 81 positive for PgR (>10 fmol/mg protein), 36 negative for PgR (~10 fmol/mg protein) and 12 with no PgR status data. No patient received perioperative adjuvant chemotherapy or endocrine therapy. Among the 129 IDC/ILC patients, 20 (18 with IDC and two with ILC) suffered a recurrence within 49 months of surgery and six died from disseminated cancer. In the remaining 123 patients, the mean follow-up period was 43.4 months after surgery, ranging from 15 to 61 months.
GENE AND CHROMOSOME ALTERATIONS IN NO BREAST
CARCINOMAS
LOH on 16p, LOH on 16q and mutation of the p53 gene had already been examined in 65, 65 and 37 patients respectively (21, 24 (30) (31) (32) . Gene amplification was examined using the c-erbB-2 (pCER204) and int-L (SS6) probes (33, 34) . Mutations in exons 4-8 of the p53 gene were examined by polymerase chain reaction single-strand conformation polymorphism analysis (35) .
The mean number of gene and chromosome alterations per tumor was modulated by the formula:
where Nl is the number of alterations, including LOH on 16p, 17p, 17q and 18q, c-erbB-2 and int-T gene amplifications, and p53 gene mutations, in each tumor, and N2 is the number of gene or chromosome loci informative for gene alterations in each tumor. In this formula, n; the number of gene alteration types examined, was always 7. Because LOH on 16q occurs in breast cancer regardless of the grade of atypia (21) , this alteration was excluded from the calculation.
STATISTICAL ANALYSIS
The correlation of each gene or chromosome alteration with the histological grade was examined using the X 2 test. Disease-free survival curves were plotted by the Kaplan-Meier method and differences between the three curves were investigated by the log-rank test (36, 37) . The risk estimation of each prognostic indicator by univariate and multivariate analyses were performed by Cox's proportional hazards general linear model using the PHREG procedure of the SAS program package (SAS Institute Inc., Cary, NC) (38) . Disease-free survival curves differed significantly between the Grade 1, Grade 2 and Grade 3 groups (P = 0.004, Fig. 1 Table 4 ). Disease-free survival rates differed between the nO groups with 0-0.9, 1.0-2.9 and 3.0 or more alterations (p = 0.01). The 4-yr disease-free survival rates were 93% in the group with 0-0.9 alterations, 80% in that with 1.0-2.9 alterations and 65% in the group with 3.0 or more alterations (Fig. 2) .
RESULTS
After the exclusion of the Grade 1 cases, we drew survival curves for five subgroups: a, Grade 2 with a gene or chromosome alteration score of 0-0.9 (n =23); b, Grade 2 with a score of 1.0-2.9 (n = 21); c, Grade 3 with a score of 0-0.9 (n = 10); d, Grade 3 with a score of 1.0-2.9 (n =27); and e, Grades 2 and 3 with a score of 3.0 or more (n = 28). Subgroups d and e showed significantly higher recurrence rates than the other subgroups (p < 0.001) (Fig. 3) .
The risk ratio of the nO carcinoma group with 1.0-2.9 gene alterations was 2.33 (95% CI 0.62-8.77) and that of the group with 3.0 or more gene alterations was 5.56 (95% CI 1.51-20.6) if they were compared with the group with no gene alteration. The trend of increasing risk ratio was statistically significant. However, all these indicators were no more significant when histological grade was included in the same model (Table 5) . - Table 4 . Correlation between the number of gene alterations and the histological grade of atypia in nO invasive breast carcinomas *p < 0.001 between two groups Total for scores 0-2.9 In the Cox's univariate regression model analysis, histological Grade 3 (risk ratio 5.07, 95% CI 1.69-15.17), LOH on 18q (risk ratio 4.72, CI 1.86-11.96) and int-T amplification (risk ratio 3.84, CI 1.47-10.00) were significantly correlated with recurrence (Table 3) . 18q (p = 0.02) and int-2 (p = 0.02) were still significantly correlated with recurrence after being adjusted for histological grade (Table 3 ). In another multivariate regression model analysis in which all variables were included simulta- 
DISCUSSION
In nO breast IDC/ILC, LOH on 16q was confmned as occurring frequently regardless of difference in histological grade, whereas LOH on 17p, 17q and 18q,p53 mutationand c-erbB-2 amplification were accumulatedin the Grade 3 group.LOH on 18qand int-2 gene amplification were indicators of high recurrence rate in nO IDC/ILC, and the impact of these two alterations was of independent significance on early recurrence in a multivariate analysis. Several studies have shown the importance of p53 gene mutations and nuclear immunoreaction of the p53 protein as a prognostic indicatorin nO breast cancer (12, 13) . In a case-control study,Iwaya,et al. showed thatp53 immunoreaction in cancer cell nuclei was a significant indicator of recurrence within 2 yrs of curative surgical therapy (11). The results of the present study differ from those of previous studies in that mutations of the p53 gene did not correlate with a high recurrence rate. Longer follow-up and comparison of the p53 gene mutation status with nuclear p53 protein immunoreactivity for individual patients would be necessary to ascertain the role of p53 in nO cancer recurrence. It is still unclear whetherc-erbB-2 gene amplification and overexpression of its protein have a significantimpact on the prognosis of nO breast carcinomas (39, 40) . Amplification of c-erbB-2 alone was of no significance as a prognosticfactor in the nO cancer group even after excluding DCIS and predominantly DCIS. The number of these gene and chromosome alterations was shown to correlatewith a high recurrence rate in invasivenO breast cancers. In the majority of cases, disease-free survival curves significantly differed between the group with the gene or chromosome alteration score of 3.0 or more and the group with a score of 1.0-2.9. However, among Grade 3 cases, the curves did not differ between the group with a score of 3.0 or more and the group with a score of 1.0-2.9. The Grade 3 case group with the alteration score of 0-0.9 tended to be of better prognosis. These data and the results of the multivariate analysis indicated that the histological grade was superior to the accumulation of the eight gene and chromosome alterations that were examined in the present study as a practical prognosticfactor of nO breast cancer.
The accumulation of alterations of tumor-associated genes or chromosome sites were not investigated in the present study. Multicolor fluorescence in situ hybridization and comparative genomic hybridization methods have recently allowed the accumulation of a large number of gene and chromosomealterations to be observed in breast cancers (41) (42) (43) (44) (45) . Applicationof these novel methods, which can analyze a large number of chromosome alterations at the same time, would be usefulin the detectionof nO breast cancer patients at high risk of early recurrence.
In the presentstudy, histological type and the histological grade of atypia were confmned as indicators of a high-risk group for early recurrence of nO breast carcinomas. Grade 1 IDC as well as histologically low-risk types such as DCIS and predominantly DCIS, medullary carcinoma, mucinous carcinoma and tubular carcinoma, were confmned as carrying a low risk of early recurrence, whereas Grade 3 IDC/ILC, which showed a 4-yr recurrence rate of 23%, was consideredto carry a high risk factor for early recurrence. In the Grade 2 group, the 4-yr recurrence rate was 5%, but recurrence tended to occur slowly. According to the data of Yoshimoto, et al., nuclear grade 3 is a prognostic indicator of early recurrence but not of recurrence after 5 years. While the disease-free survivalrate of their nuclear grade 3 group decreased abruptlywithin5 years and reached a plateauthereafter, that of the nuclear grade 2 group decreasedgraduallyand in a linear manner even after 5 years (5). Because the grade of nuclearatypia is one of the constituents of the histological Grade, and both are well correlated, histological grade 2 might be an indicator of late recurrence, but not of early recurrence.
Toidentifygroupsat highrisk of recurrence in multi-institutional protocolstudiesfor the efficacyof adjuvanttherapies, variationsin the criteriafor histological or nuclear grading betweeninstitutions should be reduced to a minimum. Such variations may originate largely from interobserver deviations in diagnostic criteria and in part from variations in the procedures for specimen processing among institutes. It has been shown that, when a grading scheme with specifiedguidelines is used, good reproducibility of grading can be achieved among pathologists (46, 47) . When these difficulties are overcome, histological grading or nuclear grading will be a practicaland more reliableprognostic indicator for nO breast carcinomas. Activetreatment for suchpoor prognostic cases would be recommended.
